33
Participants
Start Date
October 16, 2012
Primary Completion Date
April 10, 2017
Study Completion Date
April 10, 2017
Pasireotide LAR
Intramuscular administration of pasireotide LAR was repeated every month (1 month = 28 days) for 12 months in core phase. It was permitted to increase the dose up to 60 mg in a patient showing the following biochemical test results after 3 and 6 months of study treatment: mean GH levels ≥2.5 µg/L and/or IGF-1 \> ULN. In the event of any problem with tolerability, it was permitted to reduce the next lower dosage level at any time.
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Toyoake
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Kitakyushu
Novartis Investigative Site, Fukushima
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Kobe
Novartis Investigative Site, Morioka
Novartis Investigative Site, Kagoshima
Novartis Investigative Site, Isehara
Novartis Investigative Site, Kawasaki
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Kyoto
Novartis Investigative Site, Sendai
Novartis Investigative Site, Okayama
Novartis Investigative Site, Osaka
Novartis Investigative Site, Suita
Novartis Investigative Site, Tokorozawa
Novartis Investigative Site, Shizuoka
Novartis Investigative Site, Bunkyo Ku
Novartis Investigative Site, Bunkyo-ku
Novartis Investigative Site, Itabashi-ku
Novartis Investigative Site, Minato Ku
Novartis Investigative Site, Shinjuku Ku
Novartis Investigative Site, Chiba
Novartis Investigative Site, Osaka
Novartis Investigative Site, Yamagata
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY